-
1 Comment
Chiome Bioscience Inc is currently in a long term downtrend where the price is trading 10.8% below its 200 day moving average.
From a valuation standpoint, the stock is 73.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.8.
Chiome Bioscience Inc's total revenue rose by 2.2% to $169M since the same quarter in the previous year.
Its net income has increased by 11.9% to $-206M since the same quarter in the previous year.
Based on the above factors, Chiome Bioscience Inc gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | TSE |
| CurrencyCode | JPY |
| ISIN | JP3205350006 |
| Market Cap | 9B |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.5 |
| Dividend Yield | None |
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. The company also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody production; and antibody generation services using the ADLib system. Its product pipeline under Phase 1 trial comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer (TNBC). The company's product pipeline under preclinical study includes PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC; BMAA, an anti-semphorin3a antibody for treating renal and other diseases; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis; and PXLR, an anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. It serves universities, research institutions, diagnostic companies, and pharmaceutical companies. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4583.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
